Company Profile
ADC Therapeutics Stock Price, News & Analysis
- Ticker:
- ADCT
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- Switzerland
Stock performance
1.13 USD (+5.61%)
Close
Last updated: August 6, 2026
403M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ADCT closed up 5.61% at $1.13. No new same-company headline was identified in the current news window.
Company overview
Business overview
ADC Therapeutics is an oncology company focused on antibody-drug conjugates for cancer. Its platform is built around delivering cytotoxic payloads directly into tumor cells.
Geographic Base and Sector Classification
Headquartered in Switzerland and listed on NASDAQ as an ADR, ADC Therapeutics has a global oncology-biotech profile.
Business Model Characteristics
The company depends on clinical data, commercial execution, and the ability to sustain a differentiated ADC franchise.
Position Within the Biotechnology Landscape
ADC Therapeutics is a classic oncology catalyst name whose stock reacts to readouts and product execution.
Future catalysts
ADC Therapeutics’ catalysts are ZYNLONTA execution, employee-inducement grants / pipeline updates, and any commercial progress that proves the franchise can keep stabilizing. The market will focus on whether the company can turn a niche ADC into a more durable asset.
Recent news
- 01
ADC Therapeutics gewährt neuen Mitarbeitern Zuteilungen im Rahmen des Anreizplans
Source: ADC Therapeutics
- 02
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Source: ADC Therapeutics
- 03
ADC Therapeutics hält Vorträge auf bevorstehenden Investorenkonferenzen
Source: ADC Therapeutics
- 04
ADC Therapeutics to Present at Upcoming Investor Conferences
Source: ADC Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of ADC Therapeutics (ADCT)?
ADC Therapeutics (ADCT) most recently closed at 1.13 USD, a +5.61% move versus the previous session.
What is the market cap of ADC Therapeutics (ADCT)?
ADC Therapeutics currently has a market capitalization of 403M USD on BioPharmSignal.
What does ADC Therapeutics do?
ADC Therapeutics is an oncology company focused on antibody-drug conjugates for cancer. Its platform is built around delivering cytotoxic payloads directly into tumor cells.
On which exchange is ADCT stock listed?
ADC Therapeutics (ADCT) is associated with NYSE, Switzerland, Biopharma.
What is Therapeutics?
ADC Therapeutics’ catalysts are ZYNLONTA execution, employee-inducement grants / pipeline updates, and any commercial progress that proves the franchise can keep stabilizing.
Which conditions is ADC Therapeutics targeting with Therapeutics?
ADC Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does ADC Therapeutics describe recent progress with Therapeutics?
ADC Therapeutics’ catalysts are ZYNLONTA execution, employee-inducement grants / pipeline updates, and any commercial progress that proves the franchise can keep stabilizing.
What future catalysts are investors watching for ADC Therapeutics?
ADC Therapeutics’ catalysts are ZYNLONTA execution, employee-inducement grants / pipeline updates, and any commercial progress that proves the franchise can keep stabilizing. The market will focus on whether the company can turn a niche ADC into a more durable asset.